SBIR/STTR Research Award
Next-Generation Adenovirus Vaccine
Award amount
$1,074,853Program and phase
SBIR · Phase IIAward year
2019Award details
- Awarding agency
- Department of Defense
- Branch
- Defense Health Agency
- Recipient company
- TECHNOVAX INC
- Proposal award date
- 2019-09-16
- Contract end date
- 2022-02-15
- UEI
- CQC1WKNLJC41
- Solicitation number
- 15.1
- Topic code
- A15-051
Research abstract
1. Produce AdVLP 55 to address the ongoing epidemic of Adenovirus type 55 causing severe pulmonary infections and death in Asia. 2. Establish analytical methods to monitor in-process production control, characterize the final vaccine product, conduct Ad
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Production and Testing of VLP-based RSV Vaccine
- Universal VLP-Based Flu Vaccine:Broadly protective (universal) virus-like particle (VLP) based influenza vaccine that can neutralize a broad spectrum of influenza A virus subtypes.
- Next-Generation Adenovirus Vaccine
- Next Generation of Multivalent Adenovirus Vaccines Based on Novel Virus-Like Particle (VLP) Technology
- Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
9 SBIR/STTR records share this UEI (2005–2020). Reported award amounts total $10,022,344. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense